Intellia Therapeutics (NASDAQ:NTLA) Stock Price Expected to Rise, Leerink Partners Analyst Says

Intellia Therapeutics (NASDAQ:NTLA) had its price target increased by stock analysts at Leerink Partners from $27.00 to $29.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners’ price objective would indicate a potential upside of 109.84% from the company’s previous close.

A number of other analysts have also commented on NTLA. Wolfe Research reissued a “peer perform” rating on shares of Intellia Therapeutics in a report on Wednesday, November 12th. Wells Fargo & Company lifted their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Tuesday. KeyCorp set a $25.00 price target on Intellia Therapeutics in a report on Wednesday, January 28th. Chardan Capital restated a “buy” rating and set a $26.00 price objective on shares of Intellia Therapeutics in a research note on Friday, February 27th. Finally, Barclays cut their price objective on shares of Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating on the stock in a report on Friday, November 7th. Eleven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $19.59.

Intellia Therapeutics Trading Up 1.6%

NTLA opened at $13.82 on Tuesday. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.25. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -3.61 and a beta of 2.10. The company’s fifty day moving average price is $12.17 and its two-hundred day moving average price is $13.10.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company had revenue of $23.02 million during the quarter, compared to the consensus estimate of $12.17 million. During the same period in the previous year, the firm posted ($1.27) earnings per share. The firm’s revenue for the quarter was up 78.4% on a year-over-year basis. As a group, equities analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Birgit C. Schultes sold 8,508 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the transaction, the executive vice president directly owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. The trade was a 7.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP James Basta sold 10,397 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the transaction, the executive vice president owned 101,528 shares of the company’s stock, valued at approximately $935,072.88. The trade was a 9.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 53,051 shares of company stock worth $488,600 in the last quarter. 3.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Schroder Investment Management Group increased its position in Intellia Therapeutics by 1,593.4% in the second quarter. Schroder Investment Management Group now owns 406,425 shares of the company’s stock worth $3,812,000 after buying an additional 382,425 shares during the last quarter. Marex Group plc purchased a new position in shares of Intellia Therapeutics during the 2nd quarter valued at $5,849,000. JPMorgan Chase & Co. grew its stake in shares of Intellia Therapeutics by 73.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock worth $8,822,000 after acquiring an additional 396,858 shares during the period. AXQ Capital LP purchased a new stake in Intellia Therapeutics in the 2nd quarter worth about $285,000. Finally, SG Americas Securities LLC raised its stake in Intellia Therapeutics by 239.7% in the 3rd quarter. SG Americas Securities LLC now owns 131,070 shares of the company’s stock valued at $2,264,000 after acquiring an additional 92,485 shares during the period. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

More Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds / allows second in‑human trial to resume, removing a major regulatory overhang and clearing Intellia to restart an important gene‑editing program. Read More. Read More.
• Positive Sentiment: Multiple analyst upgrades and target increases (JonesTrading to Buy, Leerink & HC Wainwright bumping targets, William Blair upgrade to Outperform) have supported sentiment and likely drove buying interest. JonesTrading set a $29 PT; HC Wainwright raised its PT to $30. Read More. Read More.
• Positive Sentiment: Intellia presented longer‑term clinical data for lonvoguran (lonvo‑z) at AAAAI showing multi‑year follow‑up after a one‑time dose — reinforces the durability narrative for a key therapeutic candidate. Read More.
• Positive Sentiment: High‑profile investor interest: Cathie Wood’s Ark (coverage piece) noted buying activity in beaten‑up growth names, including Intellia — a potential source of additional demand from momentum/growth investors. Read More.
• Neutral Sentiment: Other broker moves mixed: RBC, Wells Fargo and others nudged targets modestly higher (to ~$15), while Canaccord cut its target from $54 to $48 — consensus remains wide, reflecting varying views on timelines and commercialization risk. Read More.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates across several 2026 quarters and lowered full‑year forecasts slightly even while maintaining a Buy and a $30 PT — a reminder analysts expect continued cash burn and negative earnings into 2026. This raises execution risk and could limit multiple expansion. Read More.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.